The Need for Speed: Why vertical integration is the key to streamlining complex retina clinical trials

Retina clinical trials are becoming more complex than ever. As therapies become more advanced, success depends on more than recruitment alone. It requires connected workflows, aligned partners, strong imaging expertise, and seamless execution from study start up through endpoint evaluation.

In a recent article, Lexitas CEO & Chairwoman, Jeanne Hecht, and Chief Retina Strategy Officer David Almeida, MD, MBA, PhD, explore why vertical integration may be the key to streamlining retinal clinical research without compromising quality. They challenge several common assumptions about retinal research, including why more sites doesn’t always translate to faster enrollment, how quality drives speed, and whether integration leads to conflicts of interest.

Our Visionary Insights newsletter is published once per quarter and has thousands of subscribers. To stay in touch, subscribe today.